Soleno terminates at-the-market offering agreement with Cantor Fitzgerald; $7.67M sold out of $8.88M authorized

SOLENO THERAPEUTICS INC

Terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald effective September 26, 2023.
Under the ATM prospectus, $7.67M of common stock sold out of $8.88M authorized capacity.
No further sales of common stock will be made under the ATM program.
Cantor waived the termination notice period, making termination immediate.

item 1.02 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SOLENO THERAPEUTICS INC terminated Sales Agreement with Cantor Fitzgerald & Co. (effective 2023-09-26).

Action: termination
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co.
Effective: 2023-09-26

Exact text from the filing

On September 26, 2023, Soleno Therapeutics, Inc. (the “Company”), provided notice to Cantor Fitzgerald & Co. (“Cantor”) of its election to terminate the Controlled Equity Offering Sales Agreement between them dated July 16, 2021 (the “Sales Agreement”).

View on SEC.gov

Browse all material agreements →

SOLENO THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-23-243881

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.